1 Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum
cholesterol, blood pressure and mortality: implications from a cohort of
361,662 men. Lancet 1986; ii: 933-936
2 Stamler J, Vaccaro O, Neaten J D, Wentworth D for the Multiple Risk
Factor Intervention Trial Research Group. Diabetes, other risk factors and
12-yr cardiovascular mortality for men screened in the Multiple Risk Factor
Intervention Trial. Diabetes Care. 1993;16: 434-444
3 Keys A. Seven Countries: A multivariate analysis of health and coronary
heart disease. Harvard University Press, 1980
4 Jacobs D, Blackburn H,
Higgins M et al. Report of the conference on low blood cholesterol:
mortality associations. Circ 1992; 86: 1046-1060
5 Peto R. Author commentary. Section 6.4 (pp.72-82) in: Chen J, Campbell
TC, Li J, Peto R. Diet, Life-style and Mortality in China. Oxford: Oxford
University Press 1990
6 Chen ZM, Peto R, Collins R et al. Serum cholesterol concentration and
coronary heart disease in population with low cholesterol concentrations. Br
Med J 1991; 303: 276-282
7 Szatrowski TP, Peterson AV, Shimizu Y et al. Serum cholesterol levels,
other risk factors, and cardiovascular disease in a Japanese cohort. J Chron
Dis 1984; 7: 569-584
8 Peto R, Yusuf S, Collins R. Cholesterol lowering trials in their
epidemiological context. Circ 1985; 72: 451
9 Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after
myocardial infarction. New Engl J Med 1990; 323: 1112-1119
10 Buchwald H, Varco RL, Matts JP et al. Effect of partial ileal bypass
surgery on mortality and morbidity from coronary heart disease in patients
with hypercholesterolemia. New Engl J Med 1990; 323: 946-955
11 Iribarren C, Dwyer JH, Burchfiel CM, Reed DM. Can the U-shaped relation
between mortality and serum cholesterol be explained by confounding? 33rd Ann
Conf Card Dis Epid Prev 1993. Ab-28
12 Chen Z, Keech A, Collins R, Slavin B, Chen J, Campbell TC, Peto R.
Prolonged infection with hepatitis B virus and association between low blood
cholesterol concentration and liver cancer. Br Med J 1993; 306: 890-894
13 Oliver MF. Might treatment of hypercholesterolaemia increase
non-cardiac mortality? Lancet 1991; i: 1529-1531
14 Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations
and mortality: a quantitative review of primary prevention trials. Br Med J
1990; 301: 309-314
15 Davey Smith G, Pekkanen J. Should there be a moratorium on the use of
cholesterol lowering drugs? Br Med J 1992;304:431-434
16 Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality:
the importance of considering initial level of risk. Br Med J 1993; 306:
1367-1373
17 Law MR, Thompson SG, Ward NJ et al. Assessing possible hazards of
reducing serum cholesterol. Br Med J 1994; 308: 373-379
18 Grundy SM. HMG-CoA reductase inhibitors for treatment of
hypercholesterolemia. New Engl J Med 1988; 319: 24-33
19 Bradford RH, Shear
CL, Chremos AN et al. Expanded Clinical Evaluation of Lovastatin (EXCEL)
study results. I. Efficacy in modifying plasma lipoproteins and adverse
effect profile in 8245 patients with moderate hypercholesterolemia. Arch
Intern Med 1991; 151: 43-49
20 Keech A, Collins R, MacMahon S, Armitage J, Lawson A et al. Three-year
follow-up of the Oxford Cholesterol Study: assessment of the efficacy and
safety of simvastatin in preparation for a large mortality study. Eur Heart J
1994; 15: 255-269
21 Mabuchi H, Haba T, Tatami R et al. Effects of an
inhibitor of 3-hydroxy-3-methylglutaryl Coenzyme A reductase on serum
lipoproteins and ubiquinone-l0 levels in patients with familiar
hypercholesterolemia. New Engl J Med 1981; 305: 478-482
22 Laties AM, Shear CL, Lippa EA et al. Expanded Clinical Evaluation of
Lovastatin (EXCEL) study results. II. Assessment of the human lens after 48
weeks of treatment with lovastatin. Am J Cardiol 1991; 67: 447- 453
23 Farmer JA, Washington LC, Jones PH et al. Comparative effects of
simvastatin and lovastatin in patients with hyper-cholesterolemia. Clin Ther
1992; 14: 708-717
24 The Simvastatin Pravastatin Study Group. Comparison of the efficacy,
safety and tolerability of simvastatin and pravastatin for
hypercholesterolemia. Am J Cardiol 1993; 7: 1408-1414.
25 Hunninghake DB, Stein EA, Dujovne CA et al. The efficacy of intensive
dietary therapy alone or combined with lovastatin in outpatients with
hypercholesterolemia. New Engl J Med 1993; 328: 1213-1219
26 Collins R, Keech A, Peto R et al. Cholesterol and total mortality: need
for larger trials. Br Med J 1992; 304: 1689
27 Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond
cholesterol. Modification of low- density lipoprotein that increases its
atherogenicity. New Engl J Med 1989; 320: 915-924
28 Steinberg D and Workshop Participants. Antioxidants in the prevention of
human atherosclerosis. Summary of the proceedings of a National Heart, Lung,
& Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland. Circ
1992; 85: 2338-2344
29 Carew TE, Schwenke DC, Steinberg D. Anti-atherogenic effects of probucol
unrelated to its hypercholesterolemic effect: evidence that antioxidants in
vivo can selectively inhibit LDL degradation in macrophage-rich fatty streaks
and slow the progression of atherosclerosis in the WHHL rabbit. Proc Natl
Acad Sci USA 1987; 84: 7725-7729
30 Verlangieri AJ, Bush MJ. Effects of d-a-tocopherol supplementation on
experimentally induced primate atherosclerosis. J Am Coll Nutr 1992; 11:
130-137
31 Williams RJ, Motteram JM, Sharp CH, Gallagher PJ. Dietary vitamin E and
the attenuation of early lesion development in modified Watanabe rabbits.
Atherosclerosis 1992; 94: 153-159
32 Esterbauer H, Jurgens G, Quehenberger O, Koller E. Autoxidation of human
low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E
and generation of aldehydes. J Lipid Res 1987; 28: 495-509
33 Dieber-Rotheneder M, Puhl H, Waeg G, Striegl G, Esterbauer H. Effect of
oral supplementation with D-a-tocopherol on the vitamin E content of human
low density lipoproteins and resistance to oxidation. J Lipid Res 1991; 32:
1325-1332
34 Keech A, Collins R, Peto R et al. Vitamin E supplementation inhibits LDL
oxidation in patients at risk of coronary disease taking simvastatin or
placebo. XI Int Symp Drugs Lip Met 1992: 59
35 Jandak JM, Steiner M, Richardson PD. Reduction of platelet adhesiveness
by vitamin E supplementation in humans. Thromb Res 1988; 49: 393-404
36 Mahoney CW, Azzi A.Vitamin E inhibits protein kinase C activity. Biochem
Biophys Res Comm 1988;154:694 7
37 Diplock A, Xu GL, Yeow CL, Okikola M. Relationship of tocopherol
structure to tissue uptake and prostaglandin biosynthesis. Ann NY Acad Sci
1989; 570: 72-84
38 Janero DR. Therapeutic potential of vitamin E against myocardial
ischemic-reperfusion injury. Free Rad Biol & Med 1991; 10: 315-324
39 Jialal I, Grundy SM. Preservation of the endogenous antioxidants in low
density lipoprotein by ascorbate but not probucol during oxidative
modification. J Clin Invest 1991; 87: 597-601
40 Gaziano JM, Hennekens CH. Vitamin antioxidants and cardiovascular
disease. Cur Opin Lip 1992; 3: 291-294
41 Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC.
Vitamin E consumption and the risk of coronary disease in women. N Engl J Med
1993; 328: 1444-1449
42 Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC.
Vitamin E consumption and the risk of coronary heart disease in men. N Engl J
Med 1993; 328: 1450-1456
43 Gaziano JM, Manson JE, Branch LG et al. Dietary beta carotene and
decreased cardiovascular mortality in an elderly cohort. J Am Coll Cardiol
1992; 19: 377A
44 Gey KF, Puska P, Jordan P et al. Inverse correlation between plasma
vitamin E and mortality from IHD in cross-cultural epidemiology. Am J Clin
Nutr 1991; 53: 326S-334S
45 Riemersma RA, Wood DA, Macintyre CCA, Elton RA, Gey KF, Oliver MF. Risk
of angina pectoris and plasma concentrations of vitamins A, C and E and
carotene. Lancet 1991; 337: 1-5
46 Salonen JT, Seppo Y-H, Yamamoto R et al. Autoantibody against oxidised
LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 882-887
47 Regnström J, Nilsson J, Tornvall P, Landau C, Hamsten A. Susceptibility
to low-density lipoprotein oxidation and coronary atherosclerosis in man.
Lancet 1992; 339: 1183-1186
48 Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention:
a review of the epidemiological evidence. Nutr Canc 1992; 18: 1-29
49 Editorial. Antibodies to oxidised LDL in atherosclerosis. Lancet 1992;
339: 899-900
50 Steinberg D. Antioxidant vitamins and coronary heart disease. N Engl J
Med 1993; 328: 1487-1489
51 Gaziano JM, Manson JE, Ridker PM, Buring JE, Hennekens CH. Beta carotene
therapy for chronic stable angina. Circ 1990; 82: 111-201
52 DeMaio SJ, King SB, Lembo NJ et al. Vitamin E supplementation, plasma
lipids and incidence of restenosis after percutaneous transluminal coronary
angioplasty. J Am Coll Nutr 1992; 11: 68-73
53 The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The
effect of vitamin E and beta carotene on the incidence of lung cancer and
other cancers in male smokers. N Engl J Med 1994; 330: 1029-1035
54 Hennekens CH, Buring JE, Peto R. Antioxidant vitamins – benefits not yet
proved. N Engl J Med 1994; 330: 1080-1081
55 Peto R et al. Design and analysis of randomised clinical trials
requiring prolonged observation of each patient. Brit J Cancer 1976; 34:
585-612, and 1977; 35: 1-39
56 Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Ömblus R.
Double-blind trial of aspirin in primary prevention of myocardial infarction
in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421-1425
57 Early Treatment Diabetic Retinopathy Study (ETDRS) Investigators.
Aspirin effects on mortality and morbidity in patients with diabetes
mellitus. ETDRS Report 14. J Am Med Ass 1992; 268: 1292-1300
58 Aspirin Myocardial Infarction Study Group. A randomized controlled trial
of aspirin in persons recovered from myocardial infarction. J Am Med Ass
1980; 243: 661-669
59 ISIS-2 (Second International Study of Infarct Survival) Collaborative
Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or
neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.
Lancet 1988; ii: 349-360
60 UK-TIA Study Group. United Kingdom transient ischaemic attack (TIA)
aspirin trial: interim results. Br Med J 1988; 296: 316-320
61 Prevention of Atherosclerotic Complications with Ketanserin Trial Group.
Prevention of atherosclerotic complications: controlled trial of ketanserin.
Br Med J 1989; 298: 424-430
62 World Health Organization. Ischaemic heart disease registers; report of
the Fifth Working Group, including a second revision of the operating
protocol (Copenhagen, April 26-29, 1971). Copenhagen; WHO Regional Office for
Europe, 1971